EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Predictive biomarkers for regression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2: A prospective multicenter study in Italy

Helena Frayle iD, Silvia Gori iD, Alessio Pagan, Marika Soldà, Cesare Romagnolo, Egle Insacco, Licia Laurino, Mario Matteucci, Giuseppe Sordi, Enrico Busato iD, Manuel Zorzi iD, Tiziano Maggino iD und 2 weitere

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70104 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Helena Frayle und 13 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. Hauptthemen laut MEDLINE: Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Veneto Regional Authority.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cervical intraepithelial neoplasia grade 2 (CIN2) can spontaneously regress in a sizable proportion of cases. The aim of this prospective multicenter cohort study was to identify the biomarkers associated with a high probability of regression. A total of 319 women aged 25–45 years fulfilling predefined inclusion and exclusion criteria (full visibility of transformation zone and lesion; no previous history of CIN2+ or immune impairment) were enrolled and subjected to active surveillance for 24 months. HPV genotyping, p16/ki67 expression, methylation status of FAM19A4/miR124‐2 genes, and cytology were evaluated at baseline. The probability of CIN2 regression according to the different biomarkers was evaluated through binomial logistic regression. At follow‐up, regression, persistence, and progression (evaluated on 294 women) were recorded in 165 (56%), 68 (23%), and 61 (21%) cases, respectively; no association with age was observed. Overall, 110 women underwent excisional treatment during follow‐up; 53 CIN2 and 50 CIN3+ were diagnosed. The probability of CIN2 regression significantly increased with early HPV negativity (odds ratio [OR] 6.45, 95% confidence intervals [CI] 1.68–42.6), no p16/ki67 expression (OR 2.49, 95%CI 1.38–4.52), and unmethylated status (OR 2.12, 95%CI 1.09–4.20). Our results indicate that active CIN2 surveillance could be implemented for women up to 45 years, after selection according to anatomo‐clinical criteria and biomarker status. To improve feasibility, the biomarkers can be used sequentially, taking advantage of the HPV genotyping available in primary screening tests, and eventually refining the selection by using the other biomarkers in selected subgroups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical DysplasiaUterine Cervical NeoplasmsBiomarkers, TumorHumansFemaleAdultMiddle AgedProspective StudiesItalyPapillomavirus InfectionsMicroRNAsCyclin-Dependent Kinase Inhibitor p16PapillomaviridaeDNA MethylationKi-67 AntigenNeoplasm GradingWatchful WaitingCytokines

Stichwörter der Autor:innen

CIN2HPV genotypingmethylationp16/ki67regression

Substanzen

Biomarkers, TumorMicroRNAsCyclin-Dependent Kinase Inhibitor p16MIRN124 microRNA, humanKi-67 AntigenTAFA4 protein, humanCDKN2A protein, humanCytokines

Autor:innen und Institutionen

  • Immunology and Diagnostic Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Ospedale Ca' Foncello, Local Health Unit Marca Trevigiana, Treviso, Italy.
  • Ospedale dell'Angelo, Local Health Unit Serenissima, Venezia, Italy.
  • Obstetrics and Gynaecology, Azienda Ospedale Università, Padua, Italy.
  • Ospedale San Bonifacio, Local Health Unit Scaligera, Verona, Italy.
  • Veneto Tumour Registry, Azienda Zero, Padua, Italy.

ORCID-Profile: Helena Frayle, Silvia Gori, Enrico Busato, Manuel Zorzi, Tiziano Maggino, Annarosa Del Mistro

Förderung

  • Veneto Regional Authority

Zitieren

APA

Frayle, H., Gori, S., Pagan, A., Soldà, M., Romagnolo, C., Insacco, E., Laurino, L., Matteucci, M., Sordi, G., Busato, E., Zorzi, M., Maggino, T., Del Mistro, A., & CIN2 Study Working Group (2026). Predictive biomarkers for regression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2: A prospective multicenter study in Italy. International Journal of Cancer. https://doi.org/10.1002/ijc.70104

Vancouver

Frayle H, Gori S, Pagan A, Soldà M, Romagnolo C, Insacco E, et al. Predictive biomarkers for regression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2: A prospective multicenter study in Italy. International Journal of Cancer. 2026. doi:10.1002/ijc.70104

BibTeX
@article{Frayle2026,
  author = {Frayle, Helena and Gori, Silvia and Pagan, Alessio and Soldà, Marika and Romagnolo, Cesare and Insacco, Egle and Laurino, Licia and Matteucci, Mario and Sordi, Giuseppe and Busato, Enrico and Zorzi, Manuel and Maggino, Tiziano and Del Mistro, Annarosa and CIN2 Study Working Group, CIN2 Study Working Group},
  title = {Predictive biomarkers for regression in women undergoing active surveillance for cervical intraepithelial neoplasia grade 2: A prospective multicenter study in Italy},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70104}
}
Kostenlos starten →